

**Supplemental Information****Combination Therapy of Placenta-Derived Mesenchymal Stem Cells with WKYMVm Promotes Hepatic Function in a Rat Model with Hepatic Disease via Vascular Remodeling**

Ji Hye Jun<sup>1</sup>, Sohae Park<sup>1</sup>, Jae Yeon Kim<sup>1</sup>, Ja-Yun Lim<sup>2</sup>, Gyu Tae Park<sup>3</sup>, Jae Ho Kim<sup>3</sup>, Gi Jin Kim<sup>1†</sup>

<sup>1</sup>Department of Biomedical Science, CHA University, Seongnam, 13488, Republic of Korea;


<sup>2</sup>Department of Integrated Biomedical and Life Science, College of Health Science, Korea University, Seoul, 02841, Republic of Korea; <sup>3</sup>Department of Physiology, School of Medicine, Pusan National University, Yangsan, 50612, Republic of Korea.

**†Address all correspondence and requests for reprints to:**

Gi Jin Kim, Ph.D., Associate Professor.


Department of Biomedical Science, CHA University, Seongnam, 13488, Republic of Korea; Research Institute of Placental Science, CHA University, Seongnam 13488, Republic of Korea, E-mail: gjkim@cha.ac.kr; Tel: +82-31-881-7145; Fax: +82-31-881-4102

### Supplementary Figure S1: Animal experiment scheme.



BDL, bile duct ligation; Tx, transplantation; IP, intraperitoneal; wk, week.

### Supplementary Figure S2: PD-MSCs combined with WKYMVm enhance hepatic function in the BDL rat model.



Serum analysis of the control, NTx, Tx, and Tx+WK groups for ALT (A), AST (B), total bilirubin (C), and ALB (D).  $n=3$  rats per group, mean  $\pm$  SD, \*,  $p < 0.05$  by one-way ANOVA. Con, control; NTx, nontransplantation group; Tx, PD-MSC transplantation group; Tx+WK, PD-MSCs with WKYMVm combined transplantation group; wk, week; IP, intraperitoneal.

**Supplementary Table S1: Primer sequences using quantitative real time polymerase chain reaction.**

Species	Gene	Sequence	Accession Number
Rat	VEGF	F: 5'-ACGGACAGACAGACAGACAC-3'	NM_001287114.1
		R: 5'-CTTCTGGGCTCTTCTCTCTC-3'	
	VEGFR1	F: 5'-CCACACCTGAAATCTACCAA-3'	NM_019306.2
		R: 5'-TGGGGACTGAGTATGTGAAG-3'	
	VEGFR2	F: 5'-AAGCAAATGCTCAGCAGGAT-3'	NM_013062.1
		R: 5'-TAGGCAGGGAGAGTCCAGAA-3'	
	Endoglin	F: 5'-AAGGTGTGACTGTACACAAG-3'	NM_001010968.2
		R: 5'-CCAGATCTGCATATTGTGGT-3'	
	Col I	F: 5'-CATGTTCACTTTGTGGACC-3'	NM_053304.1
		R: 5'-GCAGCTGACTTCAGGGATGT-3'	
Human	$\alpha$ -SMA	F: 5'-AACTGGTATTGTGCTGGACTCT-3'	NM_031004.2
		R: 5'-CTCAGCAGTAGTCACGAAGGA-3'	
	HNF1 $\alpha$	F: 5'-AAGATGACACGGATGACGATGG-3'	NM_012669.1
		R: 5'-GGTTGAGACCCGTAGTGTCC-3'	
	ALB	F: 5'-CTT CAA GCC TGG GCAGTAG-3'	XM_032916218.1
		R: 5'-GCACTGGCTTATCACAGCAA-3'	
	GADPH	F: 5'-TCCCTCAAGATTGTCAGCAA-3'	NM_017008.4
		R: 5'-AGATCCACAACGGATACTT-3'	
	CFD	F: 5'-GGTCACCCAAGCAACAAAGT-3'	NM_001928
		R: 5'-CCTCCTGCGTTCAAGTCATC-3'	
Human	PPARG	F: 5'-GGAAAGACAACAAACAAATC-3'	NM_138711.6
		R: 5'-TGCATTGAACTTCACAGCAA-3'	
	BGLAP	F: 5'-CACTCCTCGCCCTATTGGC-3'	NM_199173
		R: 5'-CCCTCCTGCTTGGACACAAAG-3'	
	COL1A1	F: 5'-TCCAACGAGATCGAGATCC-3'	NM_000088
		R: 5'-AAGCCGAATTCCTGGTCT-3'	
Human	GAPDH	F: 5'-CTCCTCTTCGGCAGCACA-3'	NM_002046
		R: 5'-AACGCTTCACCTAATTTGCGT-3'	

VEGF, vascular endothelial growth factor; VEGFR1, vascular endothelial growth factor receptor 1; VEGFR2, vascular endothelial growth factor receptor 2; Col I, Collagen type I;  $\alpha$ -SMA, alpha-smooth muscle actin; HNF1 $\alpha$ , hepatic nuclear factor 1 alpha; ALB, albumin; CFD, Adipsin; PPARG, peroxisome proliferator-activated receptor gamma; BGLAP, osteocalcin; COL1A1; Collagen type I.